UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities

The lancet respiratory medicine, 2017-01, Vol.5 (1), p.72-84

2017

Volltextzugriff (PDF)

Pulmonary hypertension in chronic lung disease and hypoxia

The European respiratory journal, 2019-01, Vol.53 (1), p.1801914

2019

Volltextzugriff (PDF)

Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease

The New England journal of medicine, 2021-01, Vol.384 (4), p.325-334

2021

Volltextzugriff (PDF)

High-Flow Nasal Cannula Therapy in COVID-19: Using the ROX Index to Predict Success

Respiratory care, 2021-06, Vol.66 (6), p.909-919

2021

Volltextzugriff (PDF)

Long-term Course and Prognosis of Idiopathic Pulmonary Fibrosis in the New Millennium

Chest, 2011-07, Vol.140 (1), p.221-229

2011

Volltextzugriff (PDF)

The Value and Application of the 6-Minute-Walk Test in Idiopathic Pulmonary Fibrosis

Annals of the American Thoracic Society, 2018-01, Vol.15 (1), p.3-10

2018

Volltextzugriff (PDF)

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials

The European respiratory journal, 2016-01, Vol.47 (1), p.243-253

2016

Volltextzugriff (PDF)

Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs

PloS one, 2020-03, Vol.15 (3), p.e0229445-e0229445

2020

Volltextzugriff (PDF)

Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views

Respiration, 2018-11, Vol.96 (6), p.514-524

2018

Volltextzugriff (PDF)

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis

European respiratory review, 2017-12, Vol.26 (146), p.170057

2017

Volltextzugriff (PDF)

The Future of Lung Transplantation

Chest, 2015-02, Vol.147 (2), p.309-316

Nathan, Steven D., MD, FCCP

2015

Volltextzugriff (PDF)

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis

The lancet respiratory medicine, 2017-01, Vol.5 (1), p.33-41

2017

Volltextzugriff (PDF)

Prevalence and Outcomes of Pulmonary Arterial Hypertension in Advanced Idiopathic Pulmonary Fibrosis

Chest, 2006-03, Vol.129 (3), p.746-752

2006

Volltextzugriff (PDF)

Benefits of Intensive Treadmill Exercise Training on Cardiorespiratory Function and Quality of Life in Patients With Pulmonary Hypertension

Chest, 2013-02, Vol.143 (2), p.333-343

2013

Volltextzugriff (PDF)

Progress in the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

American journal of respiratory and critical care medicine, 2023-08, Vol.208 (3), p.238-246

Nathan, Steven D

2023

Volltextzugriff (PDF)

WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension

European respiratory review, 2022-03, Vol.31 (163), p.210165

2022

Volltextzugriff (PDF)

Contemporary optimized practice in the management of pulmonary sarcoidosis

Therapeutic Advances in Respiratory Disease, 2019-08, Vol.13, p.1753466619868935-1753466619868935

2019

Volltextzugriff (PDF)

IPF in Saudi Arabia: Lessons for all

Annals of thoracic medicine, 2020-10, Vol.15 (4), p.183-184

Nathan, Steven

2020

Volltextzugriff (PDF)

Clinical implications of six-minute walk test in patients with idiopathic pulmonary fibrosis: a retrospective cohort study

Therapeutic advances in respiratory disease, 2024-01, Vol.18, p.17534666241275329

2024

Volltextzugriff (PDF)

A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease

Respiratory research, 2022-11, Vol.23 (1), p.1-307, Article 307

2022

Volltextzugriff (PDF)

The 6-min walk test as a primary end-point in interstitial lung disease

European respiratory review, 2022-09, Vol.31 (165), p.220087

2022

Volltextzugriff (PDF)

Pulmonary Hypertension and Pulmonary Function Testing in Idiopathic Pulmonary Fibrosis

Chest, 2007-03, Vol.131 (3), p.657-663

2007

Volltextzugriff (PDF)

POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes

Chest, 2016-08, Vol.150 (2), p.273-275

2016

Volltextzugriff (PDF)

Healthcare resource utilization in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD): a real-world data analysis

BMC pulmonary medicine, 2023-11, Vol.23 (1), p.1-455, Article 455

2023

Volltextzugriff (PDF)

The Red Cell Distribution Width as a Prognostic Indicator in Idiopathic Pulmonary Fibrosis

Chest, 2013-06, Vol.143 (6), p.1692-1698

2013

Volltextzugriff (PDF)

1 – 25 von 1.682

Suche als RSS-Feed

Aktive Filter

ThemaSurgery

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.490)
Mit Volltextzugriff
(1.468)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities

Pulmonary hypertension in chronic lung disease and hypoxia

Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease

High-Flow Nasal Cannula Therapy in COVID-19: Using the ROX Index to Predict Success

Long-term Course and Prognosis of Idiopathic Pulmonary Fibrosis in the New Millennium

The Value and Application of the 6-Minute-Walk Test in Idiopathic Pulmonary Fibrosis

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials

Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs

Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis

The Future of Lung Transplantation

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis

Prevalence and Outcomes of Pulmonary Arterial Hypertension in Advanced Idiopathic Pulmonary Fibrosis

Benefits of Intensive Treadmill Exercise Training on Cardiorespiratory Function and Quality of Life in Patients With Pulmonary Hypertension

Progress in the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension

Contemporary optimized practice in the management of pulmonary sarcoidosis

IPF in Saudi Arabia: Lessons for all

Clinical implications of six-minute walk test in patients with idiopathic pulmonary fibrosis: a retrospective cohort study

A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease

The 6-min walk test as a primary end-point in interstitial lung disease

Pulmonary Hypertension and Pulmonary Function Testing in Idiopathic Pulmonary Fibrosis

POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes

Healthcare resource utilization in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD): a real-world data analysis

The Red Cell Distribution Width as a Prognostic Indicator in Idiopathic Pulmonary Fibrosis

Aktive Filter

Suchergebnisse filtern